Savara (SVRA) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 4, 2026, to be held virtually, with key votes on board elections, capital structure, incentive plans, auditor ratification, and executive compensation.

• Company is preparing for potential commercial launch of molgramostim inhalation solution (MOLBREEVI) for autoimmune PAP, with regulatory reviews ongoing in the US, EU, and UK.

• Recent financial actions include $149.5 million equity financing, a $75 million royalty funding agreement, and an amended debt facility for up to $75 million upon FDA approval.

Voting matters and shareholder proposals

• Election of six directors for one-year terms.

• Amendment to Certificate of Incorporation to increase authorized common stock from 300 million to 600 million shares.

• Amendment to 2024 Omnibus Incentive Plan to add 18.9 million shares for equity awards.

• Ratification of RSM US LLP as independent auditor for fiscal 2026.

• Advisory vote on executive compensation (say-on-pay).

Board of directors and corporate governance

• Board consists of six members with diverse expertise in pharma, finance, and governance.

• All directors except the CEO are independent under Nasdaq standards.

• Board committees: Audit, Compensation, and Nominating & Governance, all with independent members.

• Lead Independent Director role established; board meets at least quarterly.

• Director resignation policy in place for failed re-elections.